Evidence map›Paper›PMID 27166817›Full record

ArticleBiophysical journal2016

Effects of Modified Parvalbumin EF-Hand Motifs on Cardiac Myocyte Contractile Function.

Michelle L Asp, Frances V Sjaastad, Jalal K Siddiqui, Jonathan P Davis, Joseph M Metzger

Abstract read
In one paragraph

Article in Biophysical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. What Is Parvalbumin for?Biomolecules · 2022
    Review
  4. Article
  5. Review
  6. Cytosolic CaCold Spring Harbor perspectives in biology · 2020
    Review
  7. Review
  8. Gene Transfer of Calcium-Binding Proteins into Adult Cardiac Myocytes.Methods in molecular biology (Clifton, N.J.) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michelle L AspDepartment of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, Minnesota.
Frances V SjaastadDepartment of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, Minnesota.
Jalal K SiddiquiDepartment of Physiology and Cell Biology, The Ohio State University College of Medicine, Columbus, Ohio.
Jonathan P DavisDepartment of Physiology and Cell Biology, The Ohio State University College of Medicine, Columbus, Ohio.
Joseph M MetzgerDepartment of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, Minnesota. Electronic address: metzgerj@umn.edu.

Funding

Novel calcium buffer for the treatment of diastolic heart failureF32HL115876 · NHLBI · UNIVERSITY OF MINNESOTA · PI LAW, MICHELLE LYNN · 2012 to 2014
$163k
NHLBI NIH HHS F32 HL115876
6 · The paper itself

Abstract

Cardiac gene delivery of parvalbumin (Parv), an EF-hand Ca(2+) buffer, has been studied as a therapeutic strategy for diastolic heart failure, in which slow Ca(2+) reuptake is an important contributor. A limitation of wild-type (WT) Parv is the significant trade-off between faster relaxation and blunted contraction amplitude, occurring because WT-Parv sequesters Ca(2+) too early in the cardiac cycle and prematurely truncates sarcomere shortening in the facilitation of rapid relaxation. We recently demonstrated that an E → Q substitution (ParvE101Q) at amino acid 12 of the EF-hand Ca(2+)/Mg(2+) binding loop disrupts bidentate Ca(2+) binding, reducing Ca(2+) affinity by 99-fold and increasing Mg(2+) affinity twofold. ParvE101Q caused faster relaxation and not only preserved contractility, but unexpectedly increased it above untreated myocytes. To gain mechanistic insight into the increased contractility, we focused here on amino acid 12 of the EF-hand motif. We introduced an E → D substitution (ParvE101D) at this site, which converts bidentate Ca(2+) coordination to monodentate coordination. ParvE101D decreased Ca(2+) affinity by 114-fold and increased Mg(2+) affinity 28-fold compared to WT-Parv. ParvE101D increased contraction amplitude compared to both untreated myocytes and myocytes with ParvE101Q, with limited improvement in relaxation. Additionally, ParvE101D increased spontaneous contractions after pacing stress. ParvE101D also increased Ca(2+) transient peak height and was diffusely localized around the Z-line of the sarcomere, suggesting a Ca(2+)-dependent mechanism of enhanced contractility. Sarcoplasmic reticulum Ca(2+) load was not changed with ParvE101D, but postpacing Ca(2+) waves were increased. Together, these data show that inverted Ca(2+)/Mg(2+) binding affinities of ParvE101D increase myocyte contractility through a Ca(2+)-dependent mechanism without altering sarcoplasmic reticulum Ca(2+) load and by increasing unstimulated contractions and Ca(2+) waves. ParvE101D provides mechanistic insight into how changes in the Ca(2+)/Mg(2+) binding affinities of parvalbumin's EF-hand motif alter function of cardiac myocytes. These data are informative in developing new Ca(2+) buffering strategies for the failing heart.

Indexed as

Amino Acid SubstitutionEF Hand MotifsMyocardial ContractionAnimalsCalciumFemaleHumansIntracellular SpaceMagnesiumMyocytes, CardiacParvalbuminsProtein ConformationRatsStructure-Activity RelationshipCalciumMagnesiumParvalbumins

Identifiers

PMID27166817
PMCPMC4940608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.